PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
 
PLoS One. 2009; 4(12): e8208.
Published online 2009 December 7. doi:  10.1371/journal.pone.0008208
PMCID: PMC2785433

Engineering Antigen-Specific T Cells from Genetically Modified Human Hematopoietic Stem Cells in Immunodeficient Mice

Derya Unutmaz, Editor

Abstract

There is a desperate need for effective therapies to fight chronic viral infections. The immune response is normally fastidious at controlling the majority of viral infections and a therapeutic strategy aimed at reestablishing immune control represents a potentially powerful approach towards treating persistent viral infections. We examined the potential of genetically programming human hematopoietic stem cells to generate mature CD8+ cytotoxic T lymphocytes that express a molecularly cloned, “transgenic” human anti-HIV T cell receptor (TCR). Anti-HIV TCR transduction of human hematopoietic stem cells directed the maturation of a large population of polyfunctional, HIV-specific CD8+ cells capable of recognizing and killing viral antigen-presenting cells. Thus, through this proof-of-concept we propose that genetic engineering of human hematopoietic stem cells will allow the tailoring of effector T cell responses to fight HIV infection or other diseases that are characterized by the loss of immune control.

Introduction

The human immune system is normally highly effective in managing exposure to the constant array of environmental antigens encountered. However, there are many instances where the immune response is ineffective in clearing infection or tumors. T cell responses, particularly cytotoxic T lymphocyte (CTL) responses, are critical in controlling viral infection or abnormal cellular growth and the failure of this response is a large factor in the inability to control these conditions[1]. Many current approaches toward treating a variety of diseases, particularly persistent diseases such as cancers or chronic viral infections, focus on the correction of defects in cellular function. Gene therapy approaches have been utilized to protect cells from infection, correct genetic defects, and enhance immune responses; however, gene-based approaches to directly enhance human cellular immune responses are relatively unexplored.

Previous studies utilizing standard gene transfer technologies have demonstrated that cloned, antigen–specific T cell receptors (TCRs) can be used to target polyclonal mature peripheral blood derived CD8+ T cells towards viral and cancer antigens [2][8]. This approach has been utilized in safely treating melanoma-afflicted individuals by “redirecting” peripheral CD8+ T cells following transduction with a vector containing an antigen specific TCR against the MART-1 antigen [9], [10]. The introduction of tumor antigen-specific cells in this instance resulted in successful tumor regression in some treated individuals [9]. However, while cells carrying the transgene in this study appeared to be long-lived, extensive ex vivo manipulation resulted in intrinsic functional defects [9]. In addition, these transduced cells also expressed endogenous TCRs and the introduction of a second TCR bypasses thymic selection and could result in auto-reactivity through cross-pairing of TCR chains or circumventing peripheral tolerance. Thus, the use of a gene therapy approach utilizing hematopoietic stem cells (HSCs) that produces functional, naive CD8+ T cells carrying a single desired antigen-specific TCR, could allow long-term engraftment, continuous generation of new effector cells, and a more efficient response through natural immune mechanisms.

Transgenic mice carrying murine TCR transgenes for a variety of antigens have been developed and are a common tool in examining cellular differentiation and function[11], [12]. Yang and Baltimore recently showed that cloned mouse TCRs introduced into murine HSCs can differentiate into antigen-specific T cells [13], [14]. Investigators have demonstrated the expression of introduced TCRs following differentiation of human progenitor cells on mouse stromal cell lines expressing the Delta-like 1 molecule [15], [16]. However, the resultant TCR-expressing cells in these studies did not undergo normal positive and negative selection events that a developing T cell would in the human thymus. Furthermore these studies did not address whether a disease fighting TCR can direct human T cell differentiation in vivo following genetic modification of human HSCs.

In the current study, we examined genetic HSC modification to produce antigen-specific T cell immunity. To determine if functional human CD8+ T cells expressing a transgenic antigen-specific human TCR can be derived from genetically modified human HSC, we utilized a human leukocyte antigen (HLA)-A*0201 restricted TCR specific for the highly conserved HIV p17 gag peptide SLYNTVATL (SL9) derived from CD8+ T cells from an infected individual. In addition, we utilized the chimeric severe combined immunodeficient mouse/human (SCID-hu) system in which mice are transplanted with human fetal thymus and liver under the renal capsule, forming a conjoint human organ that phenotypically and functionally recapitulates human thymopoiesis within the mouse [17], [18]. This provides the optimal environment for the study of human T cell differentiation within a surrogate host without having to directly involve human subjects. We and others have shown that injection of exogenous, allogeneic CD34+ HSC progenitors into sublethally irradiated SCID-hu mice results in engraftment and de novo differentiation of the exogenous cells into mature T lineage cells [19], [20]. We now demonstrate the ability to effectively transduce HSCs with an HIV-specific TCR, leading to the development of a large population of mature, functional human T cells able to specifically kill cells presenting viral peptide. This establishes a unique system to examine human TCR transgenic HSC development and facilitates the use of antigen-specific TCRs to enhance human T cell immunity and allows the close examination of the mechanisms of human T cell development and thymic selection.

Methods

Ethics Statement

Peripheral blood from HIV+ and HIV- individuals was obtained at the University of California, Los Angeles in accordance with UCLA Institutional Review Board (IRB) approved protocols under written informed consent (using an IRB-approved written consent form) by Dr. Yang and the UCLA Center for AIDS Research Virology Laboratory and was distributed for this study without personal identifying information. Resulting molecularly cloned TCRs were synthesized based on sequence information from these samples, and subsequent use did not require additional IRB approvals. Human fetal tissue was purchased from Advanced Biosciences Resources and was obtained without identifying information and thus did not require IRB approval for its use. All of the animal research described in this manuscript was performed under approval of the UCLA Animal Research Committee in accordance to all federal, state, and local guidelines.

Cloning of the HIV-1 Gag Protein, SL9 Epitope-Specific TCR

The TCR was initially isolated from the SL9-specific CTL clone 1.9, which was obtained under a UCLA IRB approved protocol, using the 5′ rapid amplification of cDNA ends (RACE) method [21]. Using overlapping PCR, the cloned TCRα and TCRβ were then joined by a picornavirus-like 2A “self-cleaving” peptide. The short 18 amino acid 2A sequence which separates the TCRα and TCRβ results in equimolar expression of the TCRα and TCRβ via a? “ribosomal skip” mechanism [22]. The TCRα-2A-TCRβ gene was cloned into the pCCL.PPT.hPGK.tcr.IRES.eGFP lentiviral vector under control of the human phosphoglycerate kinase promoter (hPGK), followed by an internal ribosomal entry site (IRES) upstream of the GFP gene [5]. The 1.9 TCR sequence was then synthetically codon optimized using sequence information based on the above clone for maximum expression in human cells and was re-inserted into the pCCL.PPT.hPGK.tcr.IRES.eGFP lentiviral vector [23].

Lentiviral Vector Production

Infectious, replication incompetent lentivirus was produced using the Invitrogen ViraPower Lentiviral Expression System with 293FT cells and the Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA). Briefly, 293FT cells were co-transfected simultaneously with the TCR containing pCCL.PPT.hPGK.1.9.IRES.eGFP plasmid, the pCMV-ΔR8.2-Δvpr packaging construct, and the pCMV-VSV-G vesicular stomatitis virus glycoprotein (VSV-G) expressing plasmid. Control eGFP expressing vectors were derived from the pCCL.PPT.hPGK.eGFP construct (in place of the TCR containing construct) in a similar manner. Supernatant was harvested from transfected 293FT cells 24 hours following transfection, filtered using a 0.22 µm sterile filter, and concentrated by centrifugation using a Beckman SW32 rotor at 30,000 rpm. Pellets were resuspended in phosphate buffered saline overnight at 4°C and frozen in aliquots at −80°C until used. Titration of the vector stocks and specificity of the TCR was performed on Jurkat T cells by limiting dilution and flow cytometry for eGFP and SL9-specific tetramer staining. Alternatively, the pCCL.PPT.hPGK.1803.IRES.eGFP plasmid [5] containing the 1803 TCR was used in some experiments in place of the 1.9-containing plasmid.

TCR-Containing Vector Transduction of CD8+ PBMC

CD8+ T cells were purified from fresh human PBMC using the EasySep CD8+ T cell enrichment Kit (StemCell Technologies) and were stimulated with anti-CD3 and irradiated allogeneic PBMCs for 4 days. Cells were then transduced with the lentiviral vector overnight and incubated for 2 more days. IFN-γ production was then measured by enzyme-linked immunospot (ELISPOT) using IFN-γ specific capture and detection antibodies (Pharmingen)[24] following incubation with irradiated (3,500 rads), peptide-coated (0.1 µg/ml) 174xCEM.T1 (T1) cells (a professional antigen presenting cell line that express high levels of HLA-A*0201) cells or non-peptide coated cells. SL9 (SLYNTVATL) peptide was purchased from Anaspec Inc. Results were read by an ImmunoSpot Analyzer (Cellular Technology Ltd.).

Isolation of CD34+ HSCs

Fresh human fetal liver was obtained by Advanced Biosciences Resources Inc. or at local sties under appropriate UCLA internal review board guidelines (Alameda, CA) and homogenized by slicing the tissue into pieces with a scalpel and passing it into a 12 ml syringe fitted with a 16 gauge blunt needle several times. The tissue was then digested with collagenase, hyaluronidase, DNase in Iscoves Modified Dulbeccos Medium (IMDM) for 90 minutes at 37°. Cells were then underlayed by Ficoll and spun 2400×g for 20 minutes and the interface was collected. Cells were repeatedly washed and placed into culture overnight at a concentration of 4×106 cell/ml of RPMI 10% FCS and 0.44 mg/ml Piptazo (Piperacillin and Tazobactam). CD34+ cells were then isolated utilizing direct human CD34+ cell isolation Kit (Miltenyi) followed by magnetic activated cell sorting by an AutoMACS (Miltenyi) apparatus. Purified cells were then immediately viably frozen in 90% FCS, 10% DMSO and kept in liquid nitrogen storage until use.

Transduction of CD34+ HSCs

Purified CD34+ cells were thawed from liquid nitrogen storage, washed and resuspended in 2% human serum albumin (HSA) containing Yssel's medium and placed into a 6-well plate coated with 20 µg/ml retronectin (Takara Bio, Inc.) with the lentiviral vector at a multiplicity of infection (MOI) of 1 overnight at 37°C. Cells were then washed, placed in plain minimal essential medium, and then injected into human thymic implants in SCID-hu mice. To determine transduction efficiency, 1×105 cells were removed prior to injection and cultured in IMDM containing 20%FCS, 50 ng/ml of IL-3, IL-6, and SCF for 3 days. eGFP expression was then assessed by flow cytometry.

SCID-hu Mice

Human fetal liver and thymus SCID-hu mice were constructed as previously described [18], [25]. Mice were irradiated with 300 rads from a colbalt-60 source to clear endogenous thymocytes from transplanted human tissue prior to implantation of 1×106 human HSCs per implant. To assess human tissue, mice were surgically biopsied utilizing survival surgical techniques as described [25].

Flow Cytometry

Cells were phenotypically analyzed using monoclonal antibodies specific for human CD3, CD45, CD4, CD8 (Coulter) and CD27, CD45RA, CCR7, and HLA-DR (eBioscience) conjugated to phycoerythrin (PE), electron coupled dye (ECD), allophycocyanin, PE-cychrome5 (PC5), or PE-cychrome 7 (PC7). Tetramer expressing cells were identified utilizing MHC Class I tetramer containing the SL9 peptide conjugated to PE (Coulter). Cells were assessed either by a Coulter FC500 instrument or a Becton Dickinson LSR2 instrument and results were analyzed FlowJo software.

Measurement of Functional Transgenic SL-9 Specific TCR Activity

To assess the ability of thymocytes containing the transgenic TCR to express IFN-γ in response to peptide specific stimulation, following biopsy and homogenization of thymic tissue, cells were placed in culture at a concentration of 1×106/ml in the presence of irradiated (3,500 rads) human T1 cells pretreated with 0.1 µg/ml SL9 peptide and 20 units/ml of IL-2 in RPMI 10% FCS. Cells were then examined for IFN-γ production by ELISPOT as described above.

CTL lytic ability was assessed by stimulating biopsied thymocytes with 2×106/ml irradiated B (Patient 1, HLA-A*0201+) cells pre-coated with SL9 peptide (1.0 µg/ml) and 2×106/ml irradiated allogeneic PBMC for 1 week in the presence of 50 units/ml of IL-2 (Roche). A fraction of cells was removed and analyzed by polychromatic flow cytometry. The remainder of cells were then placed in a standard 51chromium release assay at an effector to target cell ratio of 10[ratio]1 for 5 hours using irradiated (3,500 rads) 174xCEM.T2 (T2) cells (which are also HLA-A*0201+) coated with SL9 peptide (1.0 µg/ml) as targets.

Results

Isolation and Cloning of HIV-Specific TCR

To test the feasibility of directed T cell development following transduction of HSC with a human TCR, we utilized a human leukocyte antigen (HLA)-A*0201 restricted TCR specific for the highly conserved HIV p17 gag peptide SLYNTVATL (SL9) derived from CD8+ T cells from an infected individual. To isolate this TCR, peripheral blood mononuclear cells (PBMCs) from an HIV infected individual were selected by culturing cells in the presence of the SL9 peptide [26][28]. Full-length α and β TCR genes from a CTL clone (termed 1.9) specific for SL9 were amplified using reverse transcriptase polymerase chain reaction (PCR). The sequence was then optimized for expression and subsequently cloned into a lentiviral vector under the control of a human phosphoglycerate kinase (hPGK) promoter element. The unique TCR α and β genes, specific for viral antigen, were placed into this vector separated with a 2A self-cleaving peptide (or “skip” peptide) where the two chains are expressed together with high efficiency [29](Figure 1A). This vector further contains an internal ribosomal entry site (IRES) to allow expression of the enhanced green fluorescent protein (eGFP) marker gene. To initially assess the antigen specificity and expression of the 1.9 TCR, we transduced Jurkat T cells and observed efficient and linked expression of the 1.9 TCR and eGFP (Figure 1B). To assess the functional competence of this TCR to induce cytokine responses, mature human peripheral blood mononuclear cell (PBMC)-derived CD8+ T cells were transduced and stimulated with an irradiated SL9 peptide-pulsed HLA-A*0201+ professional antigen presenting cell line. This effectively induced IFN-γ production and demonstrates that the expression of this TCR in CD8+ T cells can allow antigen-specific functional responses (Figure 1C). In all, this demonstrates the isolation of a functional, SL9 reactive TCR and provided the impetus towards further examination of transgenic TCR expression in a hematopoietic differentiation system.

Figure 1
Cloning and functional expression of an HIV gag SL9 epitope specific TCR.

Differentiation of Human TCR Transgenic Cells In Vivo

To determine if functional antigen-specific T cells can be derived from human TCR -transduced HSCs, CD34+ HSCs were purified from fetal liver and transduced with the cloned anti-HIV 1.9 human TCR. Transduction efficiency was typically 60–80% of CD34+ cells (data not shown). These cells (1×106 HSCs per mouse) were then injected directly into HLA-A*0201+ human thymic implants in sub-lethally irradiated SCID-hu mice. The irradiation was performed to deplete endogenous thymocytes to clear space within the thymic tissue for the newly implanted cells. Thymocytes were allowed to develop from transduced CD34+ HSCs following implantation into the human tissue and cells containing the transgenic TCR were analyzed following biopsy of the thymic tissue (Figure 2A). In the thymus, from CD34+ HSCs it typically take 1–3 weeks to begin the development of immature CD34-CD4+CD8+ thymocytes and an additional 2–4 weeks to begin to see the appearance of mature CD34-CD4-CD8+ or CD34-CD4+CD8- T cells. In these studies, within 4 weeks following transplantation of the transduced hematopoietic progenitor cells, a distinct population of immature CD4+CD8+ thymocytes expressing the transgenic SL9-specific TCR was observed (Figure 2B). Interestingly, even at this early time point mature CD4-CD8+ cells were beginning to emerge, indicating that differentiation into HIV specific cells can occur relatively rapidly following transplantation of TCR transduced cells. Within 7 weeks following implantation of 1.9 TCR transduced HSCs, a substantial frequency of thymocytes expressed the transgenic TCR and the majority of these cells were mature CD4-CD8+ thymocytes (Figure 2C) indicating that these cells were undergoing appropriate lineage commitment. Importantly, we further observed that these transgenic SL9-specific TCR-containing T cells were found in the spleens of reconstituted mice (Figure 3A), indicating that cells expressing the transgenic TCR can progress through thymic differentiation and home to peripheral lymphoid tissues. In subsequent studies, we also observed similar results utilizing a different, previously characterized TCR (the 1803 clone [5]) specific to the SL9 peptide, indicating that cells containing a different TCR derived from a different patient and using different TCR alpha and beta genes differentiated into thymocytes in a similar manner (data not shown).

Figure 2
Genetic manipulation of HSCs and generation of thymocytes.
Figure 3
Characterization of SL9-specific TCR transduced HSC development into T cells.

For a hematopoietic cell to successfully become a mature, functional antigen-specific CD8+ T cell, the TCR bearing cell must undergo positive and negative selection in the thymus in the context of specific HLA Class I molecules. In the absence of the proper signal from the appropriate restricting molecule, the developing T cell will fail to become a mature CD8+ T cell. To examine the ability of these TCR transgenic cells to develop in the presence or absence of the exact SL9 peptide restricted HLA molecule (HLA-A*0201), we injected SL9-specific TCR-transduced CD34+ cells into mice implanted either with HLA-A*0201+ or HLA-A*0201- thymic tissue. Mice implanted with HLA-A*0201+ thymic tissue displayed differentiation of transduced HSCs into mature CD4-CD8+ T cells that expressed the transgenic SL9 specific TCR whereas mice implanted with HLA-A*0201- thymic tissue initially developed immature CD4dimCD8- and CD4+CD8+ thymocytes[30], but no mature CD4-CD8+ cells were observed (Figure 3B). These results indicate that the appropriate restricting elements of the recipient tissue are required for the proper development of human transgenic antiviral specific TCR-containing cells into mature thymocytes and T cells. We noted development of CD8+ tetramer+ cells in the thymic tissues derived from 6 out of 7 HLA-A*0201+ fetal donors, which would express a variety of other MHC Class I molecules. This suggests that the developing cells that express this particular TCR, and are positively selected on HLA-A*0201, survive the negative selection process in the context of a wide array of other HLA molecules.

HSC-Derived Virus-Specific T Cells Are Functional and Possess Antiviral Activity

To determine the functional capacity of the newly developed viral antigen-specific TCR-containing T cells, thymic tissue from SCID-hu mice receiving the SL9 specific TCR transduced HSCs was biopsied 7 weeks after injection. Since these antigen-naïve cells lack functional activity prior to cellular activation, the naïve cells were stimulated with SL9 peptide-pulsed, irradiated HLA-A*0201+ cells. Peptide-specific stimulation of naïve, transgenic SL9-specific TCR expressing cells resulted in the normal phenotypic differentiation into cells possessing an effector phenotype [31], [32](CD8+CD45RA-CD27+CCR7-)(Figure 4). In addition, these previously naïve, SL9-antigen specific cells induced the expression of the CD4 molecule following cellular activation, similar to that described by our laboratory and others' [33]-[37]. Following 1 week in culture, these effector SL-9 specific T cells produced significant levels of IFN-γ in response to peptide-specific stimulation (Figure 5A). To assess the cytolytic capacity of genetically engineered SL9-specific T cells, SL9-specific TCR-transduced T cells were examined for their ability to lyse peptide labeled HLA-A*0201+ target cells following peptide-specific activation. These stimulated T cells significantly lysed peptide-labeled target cells in an antigen-specific manner (Figure 5B). Thus, thymocytes expressing the transgenic, SL9-specific TCR are functional in their ability to differentiate into effector T cells, release antiviral cytokines and kill antigen-expressing target cells. This demonstrates that this system can be utilized to closely examine human antigen-specific, naïve cellular responses.

Figure 4
Phenotypic CD8+ T cell differentiation following SL-9 peptide-specific stimulation of transgenic TCR expressing thymocytes.
Figure 5
Functional responses of HIV-specific TCR transgenic T cells.

Discussion

The development of vaccine strategies, particularly therapeutic vaccine strategies, against many viruses that produce chronic infections in humans has proven to be difficult. In HIV-1 infection, the CD8+ T cell CTL response plays a crucial role in controlling viral replication in the infected individual [38], [39]. Inevitably, the CTL response fails and this loss is associated with an increase in viral load and a more rapid progression to AIDS [40], [41]. One method of augmenting CTL responses is to expand autologous antigen-specific CTLs ex vivo followed by the return of these cells into the affected individual. This has been shown to be effective in immunodeficient patients for the generation and enhancement of immunity to infection and control with cytomegalovirus (CMV) and Epstein-Barr virus (EBV)[42], [43]. While autologous HIV-specific CTLs placed in infected individuals have been shown to migrate to sites in the body of viral replication and retain some of their ability to respond to virally infected cells, this has not been shown to be effective in treating HIV infected individuals [5], [44][46]. In these HIV infected individuals, these adoptively transferred CTL persisted in the body for only a relatively short period of time and did not have a significant impact on viral replication[44][46]. These cells likely lack complete functional competence and the ability to properly respond to antigen and expand as a direct result of the effects of ongoing HIV infection and CTL clonal exhaustion prior to and following ex vivo expansion. Ex vivo expansion of these dysfunctional T cells is therefore insufficient to improve the antiviral CTL response. Thus, an alternative strategy to generate naïve antigen specific CTLs that would reconstitute immune function would be beneficial to controlling viral replication. Therefore, augmenting these CTL responses with virus-specific CTL could result in better immune control of viral replication and delay or prevent disease progression.

Generation of antigen-specific T cells from hematopoietic progenitor cells has the potential to generate long-term engraftment of specific immune cells through two different mechanisms: 1) the engraftment of hematopoietic stem cells and the production of progeny cells for extended periods of time, 2) the expansion of antigen reactive cells in the periphery and the differentiation of these cells into long-term memory cells. Our results indicate that introduction of a functional TCR into a hematopoietic progenitor cell can lead to the efficient generation of antigen-specific T cells with cytotoxic capabilities. This suggests that this approach could be useful clinically.

The ability of HIV to rapidly escape immune pressure would mandate the need for several TCRs specific for multiple viral epitopes. In the current studies, rather than seeing continuous production of immature thymocytes, we observed an extended wave of thymopoiesis culminating in the appearance of mature CD8+ thymocytes. This lack of long-term engraftment may reflect transduction of a more mature progenitor cell incapable of continuous self-renewal. Alternatively, these results may reflect the inability of these transduced stem cells to locate the correct hematopoietic niche in the SCID-hu model. Consistent with either of these mechanisms, we also observed transient reconstitution in this model using HSCs derived from embryonic sources [47]. Nonetheless, our studies provide proof of principle that this approach has strong merit.

Human stem cell gene therapy is a relatively new technology. While its use clinically at the current time is limited to a subset of diseases, its potential in treating multiple human diseases is immense. A relatively new approach is to genetically manipulate hematopoietic stem cells followed by re-infusion of these cells back into the patient. Our previous SCID-hu studies demonstrated that in the context of severe HIV-induced thymocyte depletion, human HSCs can properly differentiate into normal mature thymocytes provided that HIV replication is halted by antiretroviral therapy[48][50]. Gene therapy trials have effectively demonstrated that human stem cells can be transduced with a retroviral vector and subsequently form mature human T cells in adult subjects [51]. The recent completion of a large-scale phase 2 clinical gene therapy trial highlights the fact that this type of treatment can be used as a conventional therapeutic approach for people with HIV or a variety of diseases [52]. In all, our data demonstrate that HSC transduction with a human viral antigen-specific TCR can be utilized to generate antigen-specific CTL. Our data strongly suggest that this strategy should be pursued as an effective therapy to combat viral infection in humans.

Acknowledgments

We would like to thank David Brooks and Helen Brown for their comments pertaining to this manuscript.

Footnotes

Competing Interests: The authors have declared that no competing interests exist.

Funding: This work was funded by the California Institute for Regenerative Medicine (CIRM) Grant # RC1-00149-1 (http://www.cirm.ca.gov) and the UCLA Center for AIDS Research (CFAR)(http://www.aidsinstitute.med.ucla.edu/index.html). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript

References

1. Berzofsky JA, Ahlers JD, Janik J, Morris J, Oh S, et al. Progress on new vaccine strategies against chronic viral infections. J Clin Invest. 2004;114:450–462. [PMC free article] [PubMed]
2. Johnson LA, Heemskerk B, Powell DJ, Jr, Cohen CJ, Morgan RA, et al. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J Immunol. 2006;177:6548–6559. [PMC free article] [PubMed]
3. Hughes MS, Yu YY, Dudley ME, Zheng Z, Robbins PF, et al. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum Gene Ther. 2005;16:457–472. [PMC free article] [PubMed]
4. Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA, et al. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol. 1999;163:507–513. [PubMed]
5. Joseph A, Zheng JH, Follenzi A, Dilorenzo T, Sango K, et al. Lentiviral vectors encoding human immunodeficiency virus type 1 (HIV-1)-specific T-cell receptor genes efficiently convert peripheral blood CD8 T lymphocytes into cytotoxic T lymphocytes with potent in vitro and in vivo HIV-1-specific inhibitory activity. J Virol. 2008;82:3078–3089. [PMC free article] [PubMed]
6. Miles JJ, Silins SL, Burrows SR. Engineered T cell receptors and their potential in molecular medicine. Curr Med Chem. 2006;13:2725–2736. [PubMed]
7. Cooper LJ, Kalos M, Lewinsohn DA, Riddell SR, Greenberg PD. Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J Virol. 2000;74:8207–8212. [PMC free article] [PubMed]
8. Morgan RA, Dudley ME, Yu YY, Zheng Z, Robbins PF, et al. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immunol. 2003;171:3287–3295. [PMC free article] [PubMed]
9. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126–129. [PMC free article] [PubMed]
10. Rossi JJ, June CH, Kohn DB. Genetic therapies against HIV. Nat Biotechnol. 2007;25:1444–1454. [PubMed]
11. Tian S, Maile R, Collins EJ, Frelinger JA. CD8+ T cell activation is governed by TCR-peptide/MHC affinity, not dissociation rate. J Immunol. 2007;179:2952–2960. [PubMed]
12. Pircher H, Burki K, Lang R, Hengartner H, Zinkernagel RM. Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature. 1989;342:559–561. [PubMed]
13. Yang L, Baltimore D. Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells. Proceedings of the National Academy of Sciences of the United States of America. 2005;102:4518–4523. [PubMed]
14. Yang L, Qin XF, Baltimore D, Van Parijs L. Generation of functional antigen-specific T cells in defined genetic backgrounds by retrovirus-mediated expression of TCR cDNAs in hematopoietic precursor cells. Proceedings of the National Academy of Sciences of the United States of America. 2002;99:6204–6209. [PubMed]
15. van Lent AU, Nagasawa M, van Loenen MM, Schotte R, Schumacher TN, et al. Functional human antigen-specific T cells produced in vitro using retroviral T cell receptor transfer into hematopoietic progenitors. J Immunol. 2007;179:4959–4968. [PubMed]
16. Zhao Y, Parkhurst MR, Zheng Z, Cohen CJ, Riley JP, et al. Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling. Cancer Res. 2007;67:2425–2429. [PMC free article] [PubMed]
17. Namikawa R, Weilbaecher KN, Kaneshima H, Yee EJ, McCune JM. Long-term human hematopoiesis in the SCID-hu mouse. J Exp Med. 1990;172:1055–1063. [PMC free article] [PubMed]
18. McCune JM, Namikawa R, Kaneshima H, Shultz LD, Lieberman M, et al. The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science. 1988;241:1632–1639. [PubMed]
19. Akkina RK, Rosenblatt JD, Campbell AG, Chen IS, Zack JA. Modeling human lymphoid precursor cell gene therapy in the SCID-hu mouse. Blood. 1994;84:1393–1398. [PubMed]
20. DiGiusto DL, Lee R, Moon J, Moss K, O'Toole T, et al. Hematopoietic potential of cryopreserved and ex vivo manipulated umbilical cord blood progenitor cells evaluated in vitro and in vivo. Blood. 1996;87:1261–1271. [PubMed]
21. Frohman MA. On beyond classic RACE (rapid amplification of cDNA ends). PCR Methods Appl. 1994;4:S40–58. [PubMed]
22. Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, et al. Correction of multi-gene deficiency in vivo using a single ‘self-cleaving’ 2A peptide-based retroviral vector. Nat Biotechnol. 2004;22:589–594. [PubMed]
23. Scholten KB, Kramer D, Kueter EW, Graf M, Schoedl T, et al. Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. Clin Immunol. 2006;119:135–145. [PubMed]
24. Taguchi T, McGhee JR, Coffman RL, Beagley KW, Eldridge JH, et al. Detection of individual mouse splenic T cells producing IFN-gamma and IL-5 using the enzyme-linked immunospot (ELISPOT) assay. Journal of Immunological Methods. 1990;128:65–73. [PubMed]
25. Bristol GC, Gao LY, Zack JA. Preparation and maintenance of SCID-hu mice for HIV research. Methods. 1997;12:343–347. [PubMed]
26. Johnson RP, Trocha A, Yang L, Mazzara GP, Panicali DL, et al. HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes. Fine specificity of the gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned effector cells. J Immunol. 1991;147:1512–1521. [PubMed]
27. Walker BD, Flexner C, Birch-Limberger K, Fisher L, Paradis TJ, et al. Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1. Proceedings of the National Academy of Sciences of the United States of America. 1989;86:9514–9518. [PubMed]
28. Yang OO, Kalams SA, Rosenzweig M, Trocha A, Jones N, et al. Efficient lysis of human immunodeficiency virus type 1-infected cells by cytotoxic T lymphocytes. Journal of Virology. 1996;70:5799–5806. [PMC free article] [PubMed]
29. Yang S, Cohen CJ, Peng PD, Zhao Y, Cassard L, et al. Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. Gene Ther. 2008;15:1411–1423. [PMC free article] [PubMed]
30. Terstappen LW, Huang S, Picker LJ. Flow cytometric assessment of human T-cell differentiation in thymus and bone marrow. Blood. 1992;79:666–677. [PubMed]
31. Rufer N, Zippelius A, Batard P, Pittet MJ, Kurth I, et al. Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions. Blood. 2003;102:1779–1787. [PubMed]
32. Romero P, Zippelius A, Kurth I, Pittet MJ, Touvrey C, et al. Four functionally distinct populations of human effector-memory CD8+ T lymphocytes. J Immunol. 2007;178:4112–4119. [PubMed]
33. Flamand L, Crowley RW, Lusso P, Colombini-Hatch S, Margolis DM, et al. Activation of CD8+ T lymphocytes through the T cell receptor turns on CD4 gene expression: implications for HIV pathogenesis. Proc Natl Acad Sci U S A. 1998;95:3111–3116. [PubMed]
34. Kitchen SG, Korin Y, Roth MD, Landay A, Zack JA. Costimulation of CD8+ lymphocytes induces CD4 expression and allows HIV-1 infection. J Virol. 1998;72:9054–9060. [PMC free article] [PubMed]
35. Kitchen SG, Whitmire JK, Jones NR, Galic Z, Kitchen CM, et al. The CD4 molecule on CD8+ T lymphocytes directly enhances the immune response to viral and cellular antigens. Proc Natl Acad Sci U S A. 2005;102:3794–3799. [PubMed]
36. Sullivan YB, Landay AL, Zack JA, Kitchen SG, Al-Harthi L. Upregulation of CD4 on CD8+ T cells: CD4dimCD8bright T cells constitute an activated phenotype of CD8+ T cells. Immunology. 2001;103:270–280. [PubMed]
37. Yang LP, Riley JL, Carroll RG, June CH, Hoxie J, et al. Productive infection of neonatal CD8+ lymphocytes by HIV-1. J Exp Med. 1998;187:1139–1144. [PMC free article] [PubMed]
38. Benito JM, Lopez M, Soriano V. The role of CD8+ T-cell response in HIV infection. AIDS Rev. 2004;6:79–88. [PubMed]
39. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol. 1994;68:6103–6110. [PMC free article] [PubMed]
40. Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med. 1997;3:212–217. [PubMed]
41. Huynen MA, Neumann AU. Rate of killing of HIV-infected T cells and disease progression. Science. 1996;272:1962. [PubMed]
42. Bollard CM, Kuehnle I, Leen A, Rooney CM, Heslop HE. Adoptive immunotherapy for posttransplantation viral infections. Biol Blood Marrow Transplant. 2004;10:143–155. [PubMed]
43. Bollard CM, Gottschalk S, Leen AM, Weiss H, Straathof KC, et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 2007;110:2838–2845. [PubMed]
44. Brodie SJ, Patterson BK, Lewinsohn DA, Diem K, Spach D, et al. HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death. J Clin Invest. 2000;105:1407–1417. [PMC free article] [PubMed]
45. Lieberman J, Skolnik PR, Parkerson GR, 3rd, Fabry JA, Landry B, et al. Safety of autologous, ex vivo-expanded human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte infusion in HIV-infected patients. Blood. 1997;90:2196–2206. [PubMed]
46. Brodie SJ, Lewinsohn DA, Patterson BK, Jiyamapa D, Krieger J, et al. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat Med. 1999;5:34–41. [PubMed]
47. Galic Z, Kitchen SG, Subramanian A, Bristol G, Marsden MD, et al. Generation of T lineage cells from human embryonic stem cells in a feeder free system. Stem Cells. 2009;27:100–107. [PMC free article] [PubMed]
48. Amado RG, Jamieson BD, Cortado R, Cole SW, Zack JA. Reconstitution of human thymic implants is limited by HIV breakthrough during antiretroviral therapy. J Virol. 1999;73:6361–6369. [PMC free article] [PubMed]
49. Kitchen SG, Killian S, Giorgi JV, Zack JA. Functional reconstitution of thymopoiesis following HIV infection. J Virol. 2000;74:2943–2948. [PMC free article] [PubMed]
50. Withers-Ward ES, Amado RG, Koka PS, Jamieson BD, Kaplan AH, et al. Transient renewal of thymopoiesis in HIV-infected human thymic implants following antiviral therapy. Nat Med. 1997;3:1102–1109. [PubMed]
51. Amado RG, Mitsuyasu RT, Rosenblatt JD, Ngok FK, Bakker A, et al. Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients. Hum Gene Ther. 2004;15:251–262. [PubMed]
52. Mitsuyasu R, Merigan TC, Carr A, Zack JA, Winters MA, et al. Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nature Medicine. 2009;15:285–292. [PMC free article] [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science